(Q33470429)

English

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

John Nemunaitis

5

object named as

John Nemunaitis

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Celestia Higano

1

object named as

Celestia S Higano

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

3

object named as

Eric J Small

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

Paul F Schellhammer

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Patrick A Burch

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Lianng Yuh

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Nicole Provost

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Mark W Frohlich

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

3670-3679

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

21 January 2018

A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

21 January 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and functional significance of tumour-induced dendritic-cell defects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials of atrasentan in hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24429

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24429

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33470429&oldid=2186406555"